Clinical Trial Update: A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD [Phase 3]

View source ↗

Summary

A Phase 3 randomized, double-masked trial evaluating KH902 for wet age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• KH902

Snippet

Sponsor: Chengdu Kanghong Biotech Co., Ltd. | Conditions: Neovascular Age-related Macular Degeneration | Phase 3 | Status: COMPLETED